메뉴 건너뛰기




Volumn 44, Issue 2, 2016, Pages 329-332

Commercialization of cellular immunotherapies for cancer

Author keywords

CAR T; Cellular therapy; Immunotherapy; Oncology; Solid tumours

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR;

EID: 85009819841     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20150240     Document Type: Article
Times cited : (20)

References (6)
  • 2
    • 84957442491 scopus 로고    scopus 로고
    • Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer
    • suppl abstr TPS3007
    • Beatty, G.L., O'Hara, M.H., Nelson, A.M., McGarvey, M., Torigian, D.A., Lacey, S.F., Melenhorst, J.J., Levine, B., Plesa, G. and June, C.H. (2015) Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer. J. Clin. Oncol. 33 (suppl abstr TPS3007)
    • (2015) J. Clin. Oncol. , vol.33
    • Beatty, G.L.1    O'Hara, M.H.2    Nelson, A.M.3    McGarvey, M.4    Torigian, D.A.5    Lacey, S.F.6    Melenhorst, J.J.7    Levine, B.8    Plesa, G.9    June, C.H.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.